Eidactics, San Francisco, California.
Smith-Kettlewell Eye Research Institute, San Francisco, California.
Ophthalmology. 2013 Dec;120(12):2733-2740. doi: 10.1016/j.ophtha.2013.06.003. Epub 2013 Aug 2.
To evaluate the clinical effectiveness and anatomic changes resulting from bupivacaine injection into extraocular muscles to treat comitant horizontal strabismus.
Prospective, observational clinical series.
Thirty-one comitant horizontal strabismus patients.
Nineteen patients with esotropia received bupivacaine injections in the lateral rectus muscle, and 12 patients with exotropia received bupivacaine injections in the medial rectus. Sixteen of these, with large strabismus angles, also received botulinum type A toxin injections in the antagonist muscle at the same treatment session. A second treatment was given to 13 patients who had residual strabismus after the first treatment.
Clinical alignment measures and muscle volume, maximum cross-sectional area, and shape derived from magnetic resonance imaging, with follow-up examinations for up to 3 years.
At an average of 15.3 months after the final treatment, original misalignment was reduced by 10.5 prism diopters (Δ; 6.0°) with residual deviations of 10Δ or less in 53% of patients. A single treatment with bupivacaine alone reduced misalignment at 11.3 months by 4.7Δ (2.7°) with residual deviations of 10Δ or less in 50% of patients. Alignment corrections were remarkably stable over follow-ups for as long as 3 years. Six months after bupivacaine injection, muscle volume had increased by 6.6%, and maximum cross-sectional area had increased by 8.5%, gradually relaxing toward pretreatment values thereafter. Computer modeling with Orbit 1.8 (Eidactics, San Francisco, CA) suggested that changes in agonist and antagonist muscle lengths were responsible for the enduring changes in eye alignment.
Bupivacaine injection alone or together with botulinum toxin injection in the antagonist muscle improves eye alignment in comitant horizontal strabismus by inducing changes in rectus muscle structure and length.
评估布比卡因注射眼外肌治疗共同性水平斜视的临床疗效和解剖变化。
前瞻性、观察性临床系列研究。
31 例共同性水平斜视患者。
19 例内斜视患者接受了外侧直肌布比卡因注射,12 例外斜视患者接受了内侧直肌布比卡因注射。其中 16 例斜视角度较大的患者,在同一治疗疗程中也接受了拮抗剂肌肉的肉毒毒素 A 注射。13 例初次治疗后仍有斜视的患者接受了第二次治疗。
临床矫正测量值,以及磁共振成像(MRI)得出的肌肉体积、最大横截面积和形状,随访时间长达 3 年。
末次治疗后平均 15.3 个月时,原始偏斜距离减少了 10.5 棱镜度(Δ;6.0°),53%的患者残余偏斜在 10Δ 或以下。单次布比卡因治疗可使 11.3 个月时的偏斜距离减少 4.7Δ(2.7°),50%的患者残余偏斜在 10Δ 或以下。在长达 3 年的随访中,矫正效果非常稳定。布比卡因注射后 6 个月,肌肉体积增加了 6.6%,最大横截面积增加了 8.5%,此后逐渐恢复到治疗前水平。使用 Orbit 1.8(Eidactics,旧金山,加利福尼亚州)进行计算机建模提示,在共同性水平斜视中,通过改变直肌的长度和结构,单独使用布比卡因或与拮抗剂肌肉中的肉毒毒素 A 联合使用都能改善眼位。
单独使用布比卡因或联合使用拮抗剂肌肉中的肉毒毒素 A 可以通过改变直肌结构和长度来改善共同性水平斜视的眼位。